Molecular Heart - About the company
Molecular Heart is a series A company based in Beijing (China), founded in 2022 by Xu Jinbo. It operates as a Provider of chemoproteomics platform for small molecule drug discovery. Molecular Heart has raised $115M in funding from investors like Shenzhen Capital Group, Cathay Biotech and Sequoia Capital China. The company has 79 active competitors, including 42 funded and 5 that have exited. Its top competitors include companies like Nimbus Therapeutics, Generate Biomedicines and Cradle.
Company Details
Provider of chemoproteomics platform for small molecule drug discovery. The company has created an AI-based macromolecular optimization and design platform "MoleculeOS" with uses data-driven deep learning methods to help biotechnologists quickly identify and generate the most suitable proteins and rapidly project laboratory research results on a large scale for industrial applications.
- Website
- moleculemind.com
- Email ID
- *****@moleculemind.ai
Key Metrics
Founded Year
2022
Location
Beijing, China
Stage
Series A
Total Funding
$115M in 3 rounds
Latest Funding Round
Investors
Ranked
15th among 79 active competitors
Similar Companies
Sign up to download Molecular Heart's company profile
Molecular Heart's funding and investors
Molecular Heart has raised a total funding of $115M over 3 rounds. Its first funding round was on Feb 20, 2023. Its latest funding round was a Series A round on Jun 17, 2026 for $*****. 8 investors participated in its latest round. Molecular Heart has 17 institutional investors.
Here is the list of recent funding rounds of Molecular Heart:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 17, 2026 | 1797994 | Series A | 3061243 | 1622972 | 9341975 | 8494093 |
Sep 13, 2024 | 2891864 | Series A | 7542025 | 5919272 | 5131591 | |
Feb 20, 2023 | 7529866 | Angel | 3143561 | 6451923 | 4207970 |
Access funding benchmarks and valuations. Sign up today!View details of Molecular Heart's funding rounds and investors
Molecular Heart's founders and board of directors
Founder? Claim ProfileThe founders of Molecular Heart is Xu Jinbo.
Here are the details of Molecular Heart's key team members:
- Xu Jinbo: Founder of Molecular Heart. Contact Info: 1 email address
View details of Molecular Heart's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Molecular Heart's Competitors and alternates
Top competitors of Molecular Heart include Nimbus Therapeutics, Generate Biomedicines and Cradle. Here is the list of Top 10 competitors of Molecular Heart, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
2nd |  Generate Biomedicines 2018, Somerville (United States), Public | Developer of a platform for generating novel protein-based therapeutic modalities | $693M | 66/100 | |
3rd |  Cradle 2021, Zurich (Switzerland), Series B | Provider of chemoproteomics solutions for protein design and development | $103M | 64/100 | |
4th |  EvolutionaryScale 2023, New York City (United States), Seed | Provider of an AI models for protein design | $142M | 64/100 | |
5th | Frontier Medicines 2018, San Francisco (United States), Series C | Developer of a bioinformatics platform for drug development and chemoproteomics | $236M | 64/100 | |
6th |  Profluent Bio 2022, Berkeley (United States), Series B | Provider of an artificial intelligence-based protein design platform | $150M | 64/100 | |
7th |  Eikon 2019, Millbrae (United States), Public | Protein tracking and measuring tool for drug discovery | $1.16B | 62/100 | |
8th |  Seismic 2019, Watertown (United States), Series B | AI-assisted platform for drug discovery and development | $247M | 62/100 | |
9th |  Vividion Therapeutics 2016, Oceanside (United States), Acquired | Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers | $271M | 61/100 | |
10th | Orbit Discovery 2015, Oxford (United Kingdom), Series A | Developer of a drug discovery platforms by peptide display engine | $15.7M | 59/100 | |
15th |  Molecular Heart 2022, Beijing (China), Series A | Provider of chemoproteomics platform for small molecule drug discovery | $115M | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Molecular Heart's competitors? Click here to see the top ones
Molecular Heart's Investments and acquisitions
Molecular Heart has made no investments or acquisitions yet.
News related to Molecular Heart
Media has covered Molecular Heart for 1 event in last 1 year.
•
MoleculeMind Raises Over $100 Million in Series A FinancingTMTpost•Jun 17, 2026•Cathay Biotech, Molecular Heart, Oriental Fortune Capital, Blue Bridge Capital and 4 others
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Molecular Heart
Explore our recently published companies
- Injury Case Funding - United States based, Unfunded company
- Saile Medical - New York City based, 2025 founded, Seed company
- Elm Biosciences - New York City based, 2024 founded, Seed company
- Whoranks - Wien based, 2024 founded, Funding Raised company
- Hedlum - New York City based, 2023 founded, Funding Raised company
- Granted Health - New York City based, 2023 founded, Funding Raised company
